Modified Hematopoietic Stem Cells for Myeloablative-Free Engraftment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hemoglobinopathies such as Sickle Cell Disease and Thalassemia Syndrome, including hematopoietic stem cell transplantation (HSCT), are inefficient and pose significant adverse effects due to the use of toxic myeloablative therapies, necessitating a safer and more effective approach for modifying hematopoietic stem cells (HSCs).

Innovation Solution

A method involving passing a cell suspension of HSCs through a constriction to allow a payload to enter the cells, enhancing properties like resistance to mobilization and apoptotic factors, and increasing homing to the bone marrow by modifying the HSCs with payloads such as homing receptors, cytokines, and survival factors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If toxic myeloablative therapies are used to deplete endogenous stem cells to make space for modified HSCs, then engraftment of modified HSCs is achieved, but severe short-term and long-term clinical adverse events occur

Engineering Contradiction:

Improveengraftment of modified HSCsVSAvoidsevere clinical adverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and eliminates the harmful myeloablative therapy step from the HSCT process. By using modified HSCs that inherently resist mobilization factors and apoptotic factors, the need for toxic conditioning regimens is removed, thereby eliminating severe adverse events while preserving engraftment capability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts the natural resistance of HSCs to mobilization factors (which normally limits their therapeutic utility) into a beneficial property. By harnessing and enhancing this intrinsic resistance through genetic modification, the HSCs achieve protected engraftment without requiring harmful external interventions to prevent their removal

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If small molecule-based therapies like hydroxyurea, L-glutamine and voxelotor are used, then some therapeutic effect is achieved, but limited efficacy and non-curative outcomes occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidcurative outcome

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies preliminary genetic modification to HSCs before transplantation, equipping them with enhanced resistance properties and homing capabilities in advance. This preliminary action enables the cells to achieve curative outcomes without requiring continuous small molecule therapy, transforming the approach from symptomatic management to definitive cure

Inventive Principle:

Principle #10Preliminary action

3Object-affected harmful factors

If modified HSCs are used without myeloablative preconditioning, then safer treatment is achieved, but engraftment efficiency may be reduced

Engineering Contradiction:

Improvetoxicity of treatmentVSAvoidengraftment efficiency

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent enables modified HSCs to be self-sufficient by incorporating intrinsic resistance mechanisms that allow them to protect themselves from mobilization and apoptosis. This self-service capability eliminates the need for external myeloablative conditioning, and the cells actively promote their own engraftment through enhanced homing factor expression

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified HSCs exhibit significantly increased resistance to mobilization, apoptotic, and depleting factors, along with enhanced homing and survival, enabling safer and more efficient engraftment in the bone marrow without the need for myeloablative preconditioning.

Implementation Method 1

passing a cell suspension, which comprises a population of HSC, through a constriction under one or more parameters, wherein passing the cell suspension through the constriction under the one or more parameters allows a payload to enter the HSC

Methodology Applied

Scientific EffectPhysical passage through constriction:

Data Source

PatentUS20250257322A1Modified hematopoietic stem cells and uses thereof

Publication Date: 2025.08.14 SQZ BIOTECHNOLOGIES CO

AI summary

The present disclosure provides methods for producing modified HSCs, wherein the method comprises passing a cell suspension comprising the cell and a payload through a constriction, wherein the constriction deforms the cell, thereby causing a perturbation of the cell such that the payload enters the cell. In some aspects, the payloads are capable of enhancing one or more properties of the HSCs, such that the HSCs are better engrafted within the bone marrow of a subject.